



Agenda Scientific Session – October 3, 2020

11:00 am ET (10 min) **Welcome** - Samm Masterson (introduce the planning committee) and Dr. Araya Puwanant (welcome everyone)

11:10 am ET (5 min) **Introduction Dr. Kaminski** (Deborah Gelinias, MD - Argenx)

11:15 am ET (30 min) **Open with Dr. Henry Kaminski** - Keynote Speaker

11:45 am ET (10 min) Q & A – Moderated by Araya Puwanant, MD

11:55 am ET (20 min) **Poster Break**

12:15 pm ET (5 min) **Introduction MG Diagnostics** (Christine Rowe, MBA - Alexion)

MG Diagnostics

12:20 pm ET (20 min) **Presentations on Cell-Based Assays**

- Hans Frykman, MD, PhD
LIVE CELL-BASED ASSAY FOR ANTIBODIES TO CLUSTERED ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS, CROSS VALIDATION, INTER-ASSAY STABILITY AND UTILITY IN A PAEDIATRIC COHORT SUSPECTED FOR MG
- Jeffrey Guptill, MD
VALIDATION OF A LIVE CLUSTERED CELL BASED ACETYLCHOLINE RECEPTOR ASSAY IN A COHORT OF DOUBLE SERONEGATIVE DEFINITE MYASTHENIA GRAVIS PATIENTS

12:40 pm ET (5 min) Q & A - Moderated by Araya Puwanant, MD

12:45 pm ET (15 min)

- Miriam Fichtner, MD
AFFINITY MATURATION IS REQUIRED FOR PATHOGENIC MONOVALENT IGG4 AUTOANTIBODY DEVELOPMENT IN AUTOIMMUNE MYASTHENIA GRAVIS

1:00 pm ET (5 min) Q & A - Moderated by Araya Puwanant, MD
(5-minute transition)

1:10 pm ET (15 min) Data Blitz #1: **Focused on Diagnostics**

- Ki Hoon Kim, MD
ANTI-TITIN ANTIBODIES ARE FREQUENTLY OBSERVED IN PATIENTS WITH MYASTHENIA GRAVIS WHO EXPERIENCED THE RECURRENCE OF THYMOMA
- Pritikanta Paul, MBBS
REFLEX ALGORITHM FOR IMPROVING ACCURACY OF MYASTHENIA GRAVIS AUTOANTIBODY TESTING

- Faraz S. Hussain, PhD
PROTEOMIC PROFILING MAY REVEAL NOVEL BIOMARKERS FOR MYASTHENIA GRAVIS

1:25 pm ET (5 min) Q & A - Moderated by Araya Puwanant, MD

1:30 pm ET (20 min) **Exhibit Hall Break**

1:50 pm ET (5 min) **Introduction – MG, COVID and MG Registries** (Omar Sinno, MD, MBA – UCB)

MG, COVID and MG Registries

1:55 pm ET (30 min) **Presentations on COVID-related Topics**

- Amanda Guidon, MD
FEASIBILITY AND ACCEPTABILITY OF REMOTE MONITORING OF PATIENTS WITH MYASTHENIA GRAVIS USING DIGITAL TECHNOLOGY
- Srikanth Muppidi, MD
COVID-19 ASSOCIATED RISKS AND EFFECTS IN MYASTHENIA GRAVIS (CARE-MG): AN INTERNATIONAL PHYSICIAN-REPORTED REGISTRY

2:25 pm ET (5 min) Q & A - Moderated by Shruti M. Raja, MD
(5-minute transition)

2:35 pm ET (15 min) Data Blitz #2: **Focused on COVID and Registries**

- Kevin Li, MD
KNOWLEDGE AND PERCEPTIONS OF THE COVID-19 PANDEMIC AMONG PATIENTS WITH MYASTHENIA GRAVIS
- Megan Barra, PharmD, BCPS, BCCCP
IMPACT OF A MYASTHENIA GRAVIS DRUG-DISEASE INTERACTION CLINICAL DECISION SUPPORT TOOL ON PROVIDER PRESCRIBING
- Donald Sanders, MD
THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: DESCRIPTION AND DEMOGRAPHICS

2:50 pm ET (5 min) Q & A - Moderated by Shruti M. Raja, MD

2:55 pm ET (20 min) **Poster Break**

3:15 pm ET (5 min) **Introduction MG Clinical Trials** (Tricia Gooljarsingh, PhD, CMPP - Momenta)

MG Clinical Trials

3:20 pm ET (30 min) **Presentations on Clinical Trials**

- Jeffrey Guptill, MD
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PK, AND PD OF NIPOCALIMAB (M281) IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
- James Howard, MD
TREATMENT OF PATIENTS WITH MYASTHENIA GRAVIS WITH EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT STUDY

3:50 pm ET (5 min) Q & A – Moderated by Srikanth Muppidi, MD
(5-minute transition)

4:00 pm ET (15 min) Data Blitz #3: **Trials/New Strategies**

- Richard J. Nowak, MD, MS
THE MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): DESIGN OF RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF AN ANTI-CD19 MONOCLONAL ANTIBODY IN GENERALIZED MYASTHENIA GRAVIS
- Suraj Muley, MD, FAAN
TWO-YEAR POST-MARKETING SAFETY EXPERIENCE OF ECULIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES
- Sangwook Oh, PhD
MUSCLE-SPECIFIC TYROSINE KINASE CHIMERIC AUTOANTIBODY RECEPTOR T CELLS (MUSK-CAART) AS A PRECISION CELLULAR IMMUNOTHERAPY FOR ANTIGEN-SPECIFIC B CELL DEPLETION IN MUSK MYASTHENIA GRAVIS (MG)

4:15 pm ET (5 min) Q & A - Moderated by Srikanth Muppidi, MD

4:15 pm ET (5 min) **Closing Remarks – Thank you(s) – Samm Masterson**

4:20 pm ET (30 min) **Poster Break and Exhibit Break**

****Agenda subject to change****